explore -WSS

explore

author：explore 2025-10-02 15:14:38 - browse：37879

insulin biosimilar — The suit, filed in a Texas federal court by the American Clinical Laboratory Association and PCR lab HealthTrackRx, claims the FDA does not have the authority to scrutinize lab-developed tests. Jacquelyn Martin/AP

A group representing clinical labs across the country sued the Food and Drug Administration on Wednesday over the agency’s plan to actively regulate lab-developed tests.

The suit, filed in a Texas federal court by the American Clinical Laboratory Association and PCR lab HealthTrackRx, claims the FDA does not have the authority to scrutinize lab-developed tests. When the FDA finalized its test regulation plan last month, several experts said it was only a matter of time until someone in the lab industry sued.

Tests made in labs have historically gone unregulated by the FDA, as the agency considered them low-risk when it started regulating medical devices in 1976. But the tests have since become more numerous and complex, and the regulatory gray area enabled unreliable tests to thrive and harm patients. Infamous examples include Theranos’ blood tests, as well as misleading prenatal genetic tests from a range of companies.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： Chemotherapy before breast cancer surgery might fuel metastasis

focus

WSS

There’s a way to spot data fakery. All journals should be using it

In rare move, senator releases unverified FBI source report alleging Biden bribe

Dementia risk linked to living in disadvantaged areas: Study

The creative science of coining drug names

How a small hospital in rural Puerto Rico survived Hurricane Maria

Delta passengers in Vegas fall sick while waiting on flight in triple

knowledge

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

focus

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Deliver public health messages at the right time

Bright Health sells Medicare Advantage business to Molina

A new ‘biological computer' targets cancer while sparing healthy cells

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Novel spinal cord stimulator treats paralysis without surgery

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Lawmakers grill UnitedHealth CEO on Change cyberattack

ChatGPT in medicine: STAT answers readers' burning questions

This biotech could one day make human eggs from scratch. But first, they’re trying to rethink IVF

entertainment

HHS's proposed rule does nothing to address the climate crisis

Thousands of UK hospital doctors walk out in the latest pay dispute, crippling health services

When a patient nears the end, a feared therapy can comfort

FDA panel unanimously endorses Eisai’s Alzheimer’s drug Leqembi

5 dead in mass shooting on Caribbean island of St. Vincent: Police

HHS's proposed rule does nothing to address the climate crisis

hotspot

focus

focus

entertainment